Tech Company Financing Transactions
Korsana Biosciences Funding Round
Korsana Biosciences closed a $175 million investment round on 2/18/2026. Investors included TCGX, Wellington Management Company and Fairmount Funds Management.
Transaction Overview
Company Name
Announced On
2/18/2026
Transaction Type
Venture Equity
Amount
$175,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to develop potential best-in-class therapeutics to treat neurodegenerative diseases, with an initial focus on Alzheimer's disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
221 Crescent Street? Building 23 105?
Waltham, MA 02453
USA
Waltham, MA 02453
USA
Phone
Website
Email Address
Overview
Korsana was founded with the mission to advance precision-engineered therapies, designed to address some of the biggest unmet needs in medicine. We are committed to delivering better medicines to patients suffering from devastating neurodegenerative diseases, starting with Alzheimer's disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jonathan Violin
VP - Finance
Kyle Breidenstine
VP - General Counsel
Maddy Zeylikman
Browse more venture capital transactions:
Prev: 2/18/2026: Avantos venture capital transaction
Next: 2/18/2026: Monark Markets venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs